What do systematic reviews say?

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

• Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

FLUPHENAZINE may leads to higher adverse effects‐movement disorders‐at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

• Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 2.11 [1.41, 3.15]
  3 studies · 971 participants
  Low

HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

• Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 1.64 [1.22, 2.21]
  5 studies · 170 participants
  Low

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

• Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 15.62 [0.94, 260.49]
  1 study · 69 participants
  Low